Utah Medical Products, Inc.

NASDAQ:UTMD

Medical - Instruments & Supplies

Healthcare
$72.24 +1.67%

+$1.10 today

Market cap
$205.81M
Beta
0.37
P/E (TTM)
19.6
EPS (TTM)
$3.41
Dividend yield
1.85%
52W Low $52.00High $71.81

Volume 0.02M

Average 0.01M

UTMD Total Debt

Short-term and long-term borrowings combined.

Utah Medical Products, Inc.NASDAQ: UTMD

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 21.9% from a year ago

Total debt stood at $210K at the end of Q1 FY2026, down 21.9% from a year earlier and down 6.7% from the prior quarter. Over 3 fiscal years it compounded at -12.9% a year.

Context

  • Total debt amounted to 0.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -21.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$210K-6.7% QoQ
Last fiscal yearDec 2025
$225K-33.4% YoY
Year agoMar 2025
$269K-21.9% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.9%——
1 year-33.4%——
3-year CAGR-12.9%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
225K USD
Year-over-year change
-33.4%
4-year CAGR
-13.2%

Total Debt vs competitors

How UTMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -21.9% is the 7th highest of 11, against a peer median of -3.2%.
  • Total debt amounts to 0.2% of total assets for UTMD, versus a peer median of 11.2%.
UTMD Competitors
Total Debt for UTMD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
STIMNeuronetics, Inc.Mar 2026$85.39M USD+3.5%+31.5%68.1%
CHRSCoherus Oncology, Inc.Mar 2026$54.37M USD-79.9%-56.2%20.4%
OSUROraSure Technologies, Inc.Mar 2026$40.47M USD+184.9%+1.7%10.7%
NYXHNyxoah S.A.Mar 2026€36.22M EUR+64.0%+52.4%37.0%
INFUInfuSystem Holdings, Inc.Mar 2026$22.77M USD-31.4%-54.7%23.1%
PLXProtalix BioTherapeutics, Inc.Mar 2026$8.48M USD+62.0%-37.1%8.3%
PROFProfound Medical Corp.Mar 2026$7.49M USD+53.3%-7.8%10.2%
KRMDKORU Medical Systems, Inc.Mar 2026$3.37M USD-9.8%-10.8%11.8%
CATXPerspective Therapeutics, Inc.Mar 2026$2.62M USD-31.4%+45.9%0.6%
PREPrenetics Global LimitedMar 2026$457K USD-91.1%-30.8%0.3%
UTMDUtah Medical Products, Inc.Mar 2026$210K USD-21.9%-12.9%0.2%
Peer median (excluding UTMD) —-3.2%-9.3%11.2%

Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.97M75.05M92.87M82.98M85.76M
Short-term Investments00000
Net Receivables5.13M5.54M3.39M4.09M3.52M
Inventory6.6M8.81M9.58M8.81M7.94M
Other Current Assets1K0429K448K529K
Total Current Assets73.16M89.92M106.27M96.33M97.74M
Property, Plant & Equipment (Net)10.62M10.22M10.55M9.76M9.91M
Goodwill14.1M13.35M13.69M13.58M14.05M
Intangible Assets17.76M10.38M4.95M2.87M840K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets42.48M33.96M29.19M26.21M24.8M
Total Assets115.64M123.87M135.46M122.54M122.54M
Account Payables761K1.22M769K543K911K
Short-term Debt00056K0
Tax Payables36K337K327K00
Deferred Revenue00000
Other Current Liabilities96K204K257K55K68K
Total Current Liabilities3.75M5.96M4.71M3.76M2.6M
Long-term Debt00000
Deferred Tax Liabilities2.68M2.06M1.44M1.07M451K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.68M1.26M698K00
Total Non-current Liabilities4.75M3.66M2.44M1.35M676K
Total Liabilities8.5M9.62M7.15M5.11M3.27M
Common Stock37K36K36K33K32K
Retained Earnings115.31M126.01M138.34M129.3M128.65M
Accumulated OCI(9.05M)(12.04M)(10.66M)(11.91M)(9.42M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity107.14M114.25M128.31M117.43M119.27M
Total Debt396K341K295K338K225K
Net Debt(60.58M)(74.71M)(92.57M)(82.69M)(85.53M)

Utah Medical Products, Inc.

NASDAQ:UTMD

Intrinsic Alpha fair value

Locked

Current Price

$72.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.